Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER registry

Kardiologia Polska

Volumn 68, Issue 5, 2010, Pages 539-543

  Siudak, Zbigniew ^a   Rakowski, Tomasz ^a   Dziewierz, Artur ^a   Janzon, Magnus ^b   Birkemeyer, Ralf ^c   Stefaniak, Justyna ^d   Partyka, Łukasz ^d   Zmudka, Krzysztof ^a   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Villingen Schwenningen ^*  (Germany)

^d Krakow Cardiovascular Research Institute   (Poland)

Author keywords

Abciximab; Myocardial infarction; Percutaneous coronary intervention; Registry

Indexed keywords

ABCIXIMAB;

ARTICLE; CLINICAL OBSERVATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 77953741786     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008; 29: 2909-2945.
2. Widimsky P, Bilkova D, Penicka M et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial. Eur Heart J, 2007; 28: 679-684.
3. Kalla K, Christ G, Karnik R et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation, 2006; 113: 2398-2405.
4. Andersen HR, Nielsen TT, Rasmussen K et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med, 2003; 349: 733-742.
5. Nallamothu BK, Bates ER, Herrin J et al. NRMI Investigators. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation, 2005; 111: 761-767.
6. Ellis SG, Tendera M, de Belder MA et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med, 2008; 358: 2205-2217.
7. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet, 2006; 367: 569-578.
8. Dudek D, Dziewierz A, Siudak Z et al. Transportation with very long transfer delays (> 90 min) for facilitated PCI with reduced-dose fibrinolysis in patients with ST-segment elevation myocardial infarction The Krakow Network. Int J Cardiol, 2010; 139: 218-227 (DOI: 10.1016/j.ijcard.2008.10.020).
9. Di Mario C, Dudek D, Piscione F et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet, 2008; 371: 559-568.
10. Rakowski T, Zalewski J, Legutko J et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J, 2007; 153: 360-365.
11. Maioli M, Bellandi F, Leoncini M et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol, 2007; 49: 1517-1524.
12. De Luca G, Gibson CM, Bellandi F et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart, 2008; 94: 1548-1558.
13. Dudek D, Siudak Z, Janzon M et al. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab: EUROTRANSFER Registry. Am Heart J, 2008; 156: 1147-1154.
14. Rakowski T, Siudak Z, Dziewierz A et al. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J, 2009; 158: 569-575.
15. D'Agostino RB Jr. Tutorial in biostatistics, propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med, 1998; 17: 2265-2281.
16. Montalescot G, Antoniucci D, Kastrati A et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J, 2007; 28: 443-449. (Pubitemid 47343560)
17. Antman EM, Hand M, Armstrong PW et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation, 2008; 117: 296-329.
18. Montalescot G, Barragan P, Wittenberg O et al. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med, 200; 344: 1895-903.
19. Ortolani P, Marzocchi A, Marrozzini C et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J, 2009; 30: 33-43.
20. Hassan AK, Liem SS, van der Kley F et al. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv, 2009; 74: 335-343.
21. Herrmann HC, Lu J, Brodie BR, Armstrong PW et al.; FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. J Am Coll Cardiol Cardiovasc Interv, 2009; 2: 917-924.